CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤微环境免疫抑制：实体瘤中 CAR-T 细胞进展的障碍
英文原题：Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
查看英文原题
Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞是癌症免疫治疗的一项重要进展，在血液系统恶性肿瘤中已取得显著成功。然而，在实体瘤中，肿瘤微环境（TME）中特有的免疫抑制因素会导致CAR-T 细胞疗效不佳。本文综述TME中的细胞群、细胞因子/趋化因子谱，以及代谢相关免疫抑制因素。免疫抑制性TME会导致CAR-T 细胞耗竭，并妨碍其有效浸润实体瘤。本文还回顾了近期旨在克服TME免疫抑制作用的CAR-T 细胞开发进展。克服TME免疫抑制限制的新发现，可能推动CAR-T 细胞治疗实体瘤取得成功。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer immunotherapy, with striking success in hematological cancers.
However, in solid tumors, the unique immunosuppressive elements of the tumor microenvironment (TME) contribute to the failure of CAR T cells. This review discusses the cell populations, cytokine/chemokine profile, and metabolic immunosuppressive elements of the TME.
This immunosuppressive TME causes CAR T-cell exhaustion and influences failure of CAR T cells to successfully infiltrate solid tumors. Recent advances in CAR T-cell development, which seek to overcome aspects of the TME immunosuppression, are also reviewed. Novel discoveries overcoming immunosuppressive limitations of the TME may lead to the success of CAR T cells in solid tumors.
论文信息
- 作者
- Johnson A、Townsend M、O'Neill K
- 单位
- Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA.United States
- 文献类型
- 综述
- 期刊
- Cells2022 Nov 16
- 原文标识
- PubMed 36429054 · DOI 10.3390/cells11223626
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →